| Target | cis/trans | Study | SNP | SNP location | Maj/min allele | MAF | N | βinv | seinv | Pinv | fclog | Plog | Praw |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Siglec-3 | cis | Discovery | rs10421385 | 19:51,701,891 | A/G | 0.31 | 996 | 0.412 | 0.046 | 2.9×10-18 | 1.180 | 2×10-17 | 4.7×10-18 |
| Siglec-3 | cis | Replication | rs10421385 | 19:51,701,891 | A/G | 0.26 | 337 | 0.150 | 0.072 | 0.039 | 1.060 | 0.048 | 0.035 |
| Target (abbrv.) | Siglec-3 |
| Target (full name) | Myeloid cell surface antigen CD33 |
| Somalogic ID (Sequence ID) | SL005215 (3166-92_1) |
| Entrez Gene Symbol | CD33 |
| UniProt ID | P20138 |
| UniProt Comment |
|
| Targeted by drugs (based on IPA annotation) |
|
| Biomarker applications (based on IPA annotation) |
|
All locus annotations are based on the sentinel SNP (rs10421385) and 27 proxy variant(s) that is/are in linkage disequilibrium r2 ≥ 0.8. Linkage disequilibrium is based on data from the 1000 Genomes Project, phase 3 version 5, European population and was retrieved using SNiPA's Block Annotation feature.
Download the detailed results of SNiPA's block annotation (PDF)
| Genes hit or close-by |
|